Predicting drug candidate victims of drug-drug interactions, using microdosing. - Wikidata - awgldk - TriplyDB

Predicting drug candidate victims of drug-drug interactions, using microdosing.

Predicting drug candidate victims of drug-drug interactions, using microdosing.

http://www.wikidata.org/entity/Q45348533

about

Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.Microdosing and drug development: past, present and future Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing.The application of human phase 0 microdosing trials: A systematic review and perspectives.Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing.Use of microdose phenotyping to individualise dosing of patients.Single cell measurement of telomerase expression and splicing using microfluidic emulsion cultures Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

P2860

Q34116690-10FD0F05-A859-4DFF-A188-9132850A1AF4 Q35023726-97EF1081-FCEC-47D6-8035-6E44A0289671 Q35940544-612D8B27-8BBD-4210-B5B3-B7EAEB70F23E Q36418440-CD733765-BF4B-4AC4-9F0E-46E31DF34A64 Q36618309-2DFBC771-7983-4C60-9513-E87B48A14B20 Q37701128-FE0D827D-9252-4579-9A59-140BA82FF4F4 Q37742001-FB09DABD-3F0E-4249-B24E-09811C4BCEC9 Q38057372-EB611595-B487-4949-9EBE-84A07C05D0C2 Q38186660-AD42B6F5-8E76-4E12-9793-87011283432E Q38597205-4DD0CB2B-CC3E-416A-A2CB-DAE54EC8CD99 Q38937832-C633AE33-008E-4406-A298-1BF9D8EFA2B9 Q39248701-C17BC196-394B-4511-A6B7-74D03082FA0A Q40996401-0E6D38B0-1A61-49E5-9D74-4FD3046F0DF1 Q42628030-6F36A0B6-C0C4-4834-B9DF-7656C76F97CC Q47449167-D06AF03B-9D51-4274-8793-9B8C02FF05B0 Q47925032-C3FDE95F-BF0F-4B70-939B-0C9840862A9F Q48025123-24B7EC7A-CAD2-4487-8FF2-A80ED58866D4 Q48092928-25942676-2D20-4049-AB8C-82FA7D70040A Q50668713-3F6E3EDF-4145-4A7A-8202-9252E3DC645A Q50871327-1B96A44D-2980-4B62-AEDE-048167E2CFE4

P2860

Predicting drug candidate victims of drug-drug interactions, using microdosing.

http://www.wikidata.org/entity/Q45348533

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@en

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@nl

type

label

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@en

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@nl

prefLabel

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@en

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@nl

P1433

Q45348533-C30B6EA7-46FB-42E5-BC1D-8B430C9613D5

P1476

Q45348533-1DB9C511-1A15-4AE9-80D7-B6F2B358227F

P2093

Q45348533-6854848D-0C01-456A-BDD8-053F12EBD617

Q45348533-858B71DF-7CAC-4413-A275-77CA109EF4EA

Q45348533-A8B11654-4A0B-427D-A7A6-AE9B16CF2BBF

Q45348533-EA9B23DF-CA3A-4CAC-8614-1FD362963618

P2860

Q45348533-0104BBFE-FA4E-4132-8BC5-F18E76176AC1

Q45348533-03F4B866-3CCB-4C1E-9220-DC84650292C6

Q45348533-084739F5-ABD8-42CA-8B62-F95E2F26CF90

Q45348533-15D75E10-77E4-4963-9431-87D2270A1E3C

Q45348533-241D9EC7-8CD8-404C-BE83-E2B37B4CF1C0

Q45348533-2BADCFD4-925E-4F0B-83C1-256E0B341662

Q45348533-36CCC056-BFAC-4EB0-A489-2E7121684358

Q45348533-3D2BA663-15D9-4172-9DC0-D34A2116EE4E

Q45348533-3D6BE7E0-CA2F-4218-87A0-91CAFAF0494B

Q45348533-516626B6-7B78-47F1-B7FF-C542A56537D5

P2888

Q45348533-23C83796-3CAD-4E7B-AF6C-26FA875E04A7

P304

Q45348533-5589AE0C-EA95-4B21-9721-DE1CEF0ACA37

P31

Q45348533-C30B8077-6A4B-4E01-82A4-1F31237434E3

P356

Q45348533-7B4244ED-6DF8-4A3C-94D7-E16385B46766

P433

Q45348533-83729387-E929-4AC4-AC26-74FBF46F6C1F

P478

Q45348533-E8F7D9D0-7B47-4A7F-A406-35344DCFF5C1

P50

Q45348533-467EA8AF-802C-4146-9DFE-89271A1054CC

P577

Q45348533-998535F5-A328-4173-AD48-238EBFD002DB

P6179

Q45348533-7381A788-9044-411A-9994-2976F2AAE5F0

P698

Q45348533-D371A43B-3A53-4E58-8BA2-8528AD04DDCF

P356

11597070-000000000-00000

P1433

Clinical Pharmacokinetics

P1476

Predicting drug candidate victims of drug-drug interactions, using microdosing.

@en

P2093

Graham Lappin

http://www.w3.org/2001/XMLSchema#string

Ian Morris

http://www.w3.org/2001/XMLSchema#string

Lan Tann

http://www.w3.org/2001/XMLSchema#string

Marie Croft

http://www.w3.org/2001/XMLSchema#string

P2860

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.

Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers.

Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans.

Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.

Microdosing: current and the future.

AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration.

Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique.

Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.

P2888

11597070-000000000-00000

P304

237-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11597070-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1012906746

http://www.w3.org/2001/XMLSchema#string

P698

22335429

http://www.w3.org/2001/XMLSchema#string